Coronary diseaseChronic Ischemic cardiopathyHEART DISEASE

EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?

solaci
solaci
461
0

This study randomized 3514 patients to a thin-strut biodegradable polymer everolimus-eluting stent (SYNERGY) vs. a sirolimus-eluting stent (ORSIRO) vs. a durable polymer zotarolimus-eluting stent (RESOLUTE INTEGRITY).

BIO-RESORT: polímeros vs polímeros bioabsorbibles ¿Llegamos a una meseta con los DES?The combined endpoint, the rate of target vessel failure, was similar for all three devices (8.3% for the zotarolimos-eluting stent, 6.8% for the everolimus-eluting stent, and 6.6% for the sirolimus-eluting stent).

 

Landmark analyses at one year had revealed an advantage in favor of new devices as regards the rates of revascularization and other secondary endpoints. However, at the two-year follow-up, these differences were leveled out.

 

Original title: Two-Year Clinical Outcome of All-Comers Treated with Three Highly Dissimilar Contemporary Coronary Drug-Eluting Stents in the Randomized BIO-RESORT Trial.

Presenter: Marlies M. Kok.

 

BIO-RESORT

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
EuroPCR 2018 | SPYRAL HTN-ON MED: Renal Denervation Comes Back to Life
Next article
EuroPCR 2018 | Compare-Acute: FFR or Primary Angioplasty at a 2-Year Follow-Up After Complete Revascularization
solaci
solaci

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Dr. Andrés Rodríguez - 0
Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Dr. Omar Tupayachi - 0
Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Dr. Omar Tupayachi - 0
Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Dr. Juan Manuel Pérez - 0
Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the...
Dr. Andrés Rodríguez -
SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Dr. Andrés Rodríguez - 0
Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

Dr. Juan Manuel Pérez - 0
The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

Dr. Omar Tupayachi - 0
The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...